Swissmedic introduces the Preliminary Decision Clarification Meeting for human medicinal products containing new active substances

In the course of the regulatory approval process, particularly for innovative products, situations often arise where a close dialogue with the authority is needed or beneficial, e.g. to clarify specific scientific issues or to agree on a certain response strategy to address (major) concerns that the authority has identified.
PMS implementation, the final step of the SPOR journey

PMS is the last piece of the SPOR puzzle and recently EMA published an updated PMS Roadmap. PMS implementation has been in the works for several years and during 2025 the mapping of product data from SIAMED and XEVMPD is ongoing.
Expert comment: FDA to promptly publish issued CRLs to increase transparency

FDA has recently released a large number of redacted CRLs for both approved and unapproved New Drug Applications (NDAs) and Biologics License Applications (BLAs) through their database openFDA. In July more than 200 CRLs from 2020-2024 were published and in September a further 89 previous unpublished CRLs from 2024 were added.
Swissmedic and swissethics position paper on safety considerations of FIH/early phase for clinical trials

Embarking on a First-in-Human (FIH) clinical trial is a pivotal moment in drug development, where scientific innovation meets ethical responsibility. For sponsors, this phase demands not only strategic planning but also commitment to participant safety, regulatory compliance, and data integrity.
9 things to consider before starting a tech transfer

For global Regulatory Affairs Directors. A technology transfer can be the best decision for your manufacture – or, done wrong, it could be the worst. Our experts have identified 9 red flags to look out for before initiating a tech transfer. 1. No back-up manufacturing site Preferably, do not initiate a tech transfer unless a […]
Joint Scientific Consultation in the new EU HTA Regulation

With the new EU Health Technology Assessment (HTA) Regulation, significant changes are effective for Health Technology Developers (HTDs). One of the critical components of this new regulation is the Joint Scientific Consultation (JSC), a collaborative framework between HTDs and EU HTA bodies (HTAb) designed to streamline and enhance the clinical development of medicinal products and […]
Understanding Joint Clinical Assessment (JCA)

The evolving landscape of health technology assessment (HTA) in the European Union (EU) is characterised by a significant development: the introduction of joint clinical assessments (JCA) in 2025. This initiative, part of the new HTA regulation, aims to enhance efficiency, improve the quality of evaluations, and ultimately ensure that patients gain quicker access to innovative […]
Introduction to EU Health Technology Assessment Regulation (HTAR)

On the 12th of January 2025, the new EU Health Technology Assessment (HTA) Regulation (EU-HTAR) became effective. With the introduction of the EU-HTAR, pharmaceutical companies engaged in clinical trials have entered a new era of requirements and planning. This regulation aims to harmonise and streamline the assessment processes for health technologies across EU member states, […]
Keys to managing regulatory affairs in a global MAA project

Marketing authorisation application checklist for Global Regulatory Affairs Directors Planning and delivering pharmaceutical product approvals across regions globally is not an easy undertaking. Fortunately, at Arex Advisor we are experienced in multiple facets of the process. Below, we have listed some of the key factors to ensure success, and how to steer clear of common […]
CMC in a global MAA project – what to keep on your radar

Marketing authorisation application checklist for Global Regulatory Affairs Directors Our MAA services The CMC section of the regulatory dossier stands as one of the cornerstones for achieving a successful global MAA for pharmaceutical products. Regulatory Affairs Directors must often navigate a labyrinth of requirements to ensure compliance across diverse markets, while maintaining the highest standards of […]